-
1مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Journal for immunotherapy of cancer; vol 4, iss 1, 58; 2051-1426
-
2مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Journal for immunotherapy of cancer; vol 4, iss 1, 58; 2051-1426
-
3مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Journal for immunotherapy of cancer; vol 4, iss 1, 58; 2051-1426
-
4مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Journal of hematology & oncology; vol 8, iss 1, 123; 1756-8722
مصطلحات الفهرس: Humans, Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Disease-Free Survival, Treatment Outcome, Drug Administration Schedule, Follow-Up Studies, Double-Blind Method, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Ipilimumab, Nivolumab, Immunotherapy, PD-1, CTLA-4, Cancer, Immunization, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis, article
-
5مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Journal of hematology & oncology; vol 8, iss 1, 123; 1756-8722
مصطلحات الفهرس: Humans, Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Disease-Free Survival, Treatment Outcome, Drug Administration Schedule, Follow-Up Studies, Double-Blind Method, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Ipilimumab, Nivolumab, Immunotherapy, PD-1, CTLA-4, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis, article
-
6مورد إلكتروني
المؤلفون: Tsai, Katy K
المصدر: Human vaccines & immunotherapeutics; vol 10, iss 11, 3111-3116; 2164-5515
مصطلحات الفهرس: T-Lymphocytes, Humans, Melanoma, Antineoplastic Agents, Antibodies, Monoclonal, Immunotherapy, Lymphocyte Activation, CTLA-4 Antigen, Humanized, Programmed Cell Death 1 Receptor, B7-H1 Antigen, Nivolumab, AE, adverse event, APC, antigen presenting cell, ASCO, American Society of Clinical Oncology, BMS-936559, CTLA-4, cytotoxic T-lymphocyte-associated protein 4, FDA, Food and Drug Administration, ITIM, immunoreceptor tyrosine-based inhibitory motif, ITSM, immunoreceptor tyrosine-based switch motif, Ig, immunoglobulin, MAPK, mitogen-activated protein kinase, MHC, major histocompatibility complex, MPDL3280A, NK, natural killer, ORR, objective response rate, OS, overall survival, PD, progressive disease, PD-1, programmed cell death 1, PD-L1, programmed cell death ligand 1, PD-L2, PFS, progression free survival, TCR, T cell receptor, TIL, tumor infiltrating lymphocyte, gp100, glycoprotein 100 vaccine, immunotherapy, melanoma, nivolumab, pembrolizumab, Climate-Related Exposures and Conditions, Cancer, Immunization, Immunology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences, Virology, article